Niket Nathani, MD
Critical Care Medicine · Everett, WANPI 1801113154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,099 of the $1,358 with a category attached, or 80.9%. It is spread thinly across 16 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 38 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$255
- Inari Medical, Inc.$249
- Ambu A/s$225
- Genentech, Inc.$150
- Veran Medical Technologies, Inc.$114
- Sanofi$111
- plus $254 from 10 others
What the payments were for
- Consulting fees$22517%
- Food & beverage$1,09981%
- Education$343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $255 |
| Inari Medical, Inc. | 3 | $249 |
| Ambu A/s | 1 | $225 |
| Genentech, Inc. | 2 | $150 |
| Veran Medical Technologies, Inc. | 1 | $114 |
| Sanofi | 5 | $111 |
| Amgen | 2 | $59 |
| Masimo Corporation | 1 | $42 |
| Novartis | 2 | $29 |
| GSK | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Vertos Medical, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$209
- CT THROMBECTOMY SYSTEM KIT$209
- Esbriet$125
- Spin$114
How this compares
$1,358 in reported general payments places this provider in the 85th percentile of 115 critical care medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 381 | $309,939 |
| Fasenra PenBenralizumab | 44 | $250,435 |
| OfevNintedanib Esylate | 11 | $145,817 |
| NucalaMepolizumab | 12 | $42,501 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $35,007 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $32,589 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 217 | $27,657 |
| Spiriva HandihalerTiotropium Bromide | 30 | $21,809 |
| Spiriva RespimatTiotropium Bromide | 25 | $21,159 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $17,168 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,324 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $14,951 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,102 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $10,953 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $9,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $26 | $394,818486 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $18 | $210,51993 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $255 | $52,175105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 115 critical care medicine providers in Washington.
Other critical care medicine in Everett
- Anita TsenEverett$677
- Shoaib FakhriEverett$403
- Seth HartungEverett$327
- Claude ZeifmanEverett$174
- Phillip GregoireEverett$128
- Vinay GuptaSeattle$185K
- Sara NikravanSeattle$106K
- Michael SouterSeattle$20K
- Ravinder ShergillVancouver$16K
- Oliver McElvaneySeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.